Figure S2

A

	IC_{50} (nM)		
	[peptide substrate]		
Compound	0.05 µM	0.25 µM	1 µM
MRTX1719	3	9.6	120
GSK3326595	18	41	150

B



C

	Absolute IC_{50} (nM)	
	10-Day Viability	
Compound	PK-1 (*MTAP* WT)	PK-1 (*MTAP* del)
MRTX1719	818	7.1
GSK3326595	52	24
JNJ-64619178	1.1	0.7

D



E



F





Figure S2. A. Half-maximal inhibitory concentration (IC_{50}) values of MRTX1719 and GSK3326595 in a PRMT5 biochemical assay tested with different peptide substrate concentrations. Assay runs tested with MRTX1719 included 250 nM MTA. B. MRTX1719 was run in an SDMA In-Cell Western assay (SYM11 antibody) in parental PK-1 cells (*MTAP* WT) and PK-1 cells CRISPR engineered to not express *MTAP* (*MTAP* del). C. MRTX1719, GSK3326595 and JNJ-64619178 were run in 10-Day viability assays in *MTAP* del and WT PK-1 cell lines. D. MRTX1719 washout experiment in *MTAP* del HCT116 cells showing reduction of SDMA following treatment for 3 hrs, 72 hrs or for 3 hrs followed by a 72 hr washout. E. Same experiment as in D except *MTAP* WT HCT116 parental cells cultured with 20 µM MTA were used. F. Same experiment as in D except *MTAP* WT HCT116 parental cells were used.